Equillium (EQ) Accumulated Expenses (2017 - 2026)
Equillium (EQ) posted quarterly Accumulated Expenses of $1.6 million for Q1 2026, down 42.49% year-over-year from $2.8 million in Q1 2025, and up 9.9% quarter-over-quarter from $1.5 million in Q4 2025.
Equillium (EQ) Accumulated Expenses (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Accumulated Expenses for 10 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 42.49% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 42.49% YoY), while the FY2025 annual figure was $1.5 million, down 57.97% from the prior year.
- Accumulated Expenses improved to $1.6 million in Q1 2026 per EQ's latest filing, from $1.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $7.2 million in Q4 2022 and bottomed at $69000.0 in Q2 2022.
- Historically, Accumulated Expenses has averaged $2.1 million across 5 years, with a median of $1.6 million in 2026.
- Annual changes were most pronounced in 2022 — Accumulated Expenses sank 98.16% — and 2023, when it soared 2568.12%.
- Equillium's Accumulated Expenses stood at $7.2 million in 2022, then slumped by 57.81% to $3.1 million in 2023, then advanced by 14.05% to $3.5 million in 2024, then sank by 57.97% to $1.5 million in 2025, then gained by 9.9% to $1.6 million in 2026.
- Business Quant data shows EQ's Accumulated Expenses at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 247,000.00 |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 5.65 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | 700,000.00 |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 976,000.00 |
| Dec 31, 2022 | 7.24 Mn |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 69,000.00 |
| Mar 31, 2022 | 71,000.00 |
| Dec 31, 2021 | 5.89 Mn |
| Sep 30, 2021 | 3.86 Mn |